Bucheit et al. reported that the time between the initial diagnosis of melanoma and the diagnosis of stage IV disease was significantly shorter for patients with the BRAF V600K mutation than for those with the V600E mutation, indicating that BRAF V600K mutations have greater potential for metastatic disease [55,56,57]. Here, BRAF is linked to metastatic neoplasm.